Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (CDIO) reported a net loss of $6.5 million for fiscal year 2025, consistent with the prior year's loss of $8.4 million. Revenue was minimal at $15,000, down from $35,000 in 2024, reflecting the company's early-stage commercialization efforts. Total operating expenses were $6.5 million, with general and administrative costs being the largest component at $5.0 million. The company ended the year with $5.1 million in cash, a decrease of $2.7 million from the prior year, primarily due to $5.7 million used in operating activities, partially offset by $3.4 million in net financing proceeds from stock sales. The accumulated deficit increased to $29.2 million. The company's focus remains on driving adoption of its clinical tests (Epi+Gen CHD and PrecisionCHD) and expanding its market reach, with progress noted in setting up a CLIA laboratory and international expansion to India.

Key Takeaways